Combined DNA repair gene single nucleotide polymorphisms (SNPs) in gemcitabine ( @entity14113 )/cisplatin (cis)-treated @entity1149 ( XXXX ) patients (p).

@entity11833 @entity4736 @entity4735 @entity5359 @entity20322 @entity1149 @entity20319 @entity1054 @entity67180 @entity420 @entity72205 @entity14113 @entity20823 @entity20317 @entity1349 @entity32271 @entity25980 @entity72204
UNASSIGNED: 7031 Background: We assessed SNPs in five DNA repair genes belonging to three of the major DNA repair pathways: @entity20319 @entity20322 , @entity20823 @entity32271 , @entity4735 @entity25980 , @entity4735 @entity20317 , @entity11833 @entity5359 , and @entity4736 @entity72204 and correlated the results with outcome in @entity14113 /cis-treated @entity1149 p. METHODS: 135 stage IV @entity1149 p were included from August 2001 to July 2002. TaqMan 5' nuclease assay was used to examine SNPs from baseline peripheral blood lymphocytes. RESULTS: p characteristics: median age: 61; 92% male; PS 0: 28.1%, 1: 71.9%; @entity420 : 46.7%. Overall outcome: response rate (RR) 43%; @entity1054 ( @entity1054 ) 6.78 months (m); @entity1349 ( @entity1349 ) 10.9 m. See table for distribution of genotypes. @entity1054 was 6.78 m for p with @entity4735 @entity67180 , 7.57m for @entity20317 , and 5.3 m for @entity72205 (P=0.03). In 41 p with lung metastases, @entity1054 was 6 m for p with @entity4736 C/C, 8.4 m for C/A, and 5.3 for A/A (P=0.03). @entity1054 was 11.3 m for 23 p with both @entity4735 @entity20317 and @entity4736 C/A, as compared to 6.6 m for 112 remaining p (P=0.006). A similar tendency was observed for @entity1349 (P=ns). No other significant differences according to genotype were observed. CONCLUSIONS: Heterozygosity for both @entity4735 751 and @entity4736 may be a predictive marker of chemosensitivity. [Figure: see text] No significant financial relationships to disclose.
